Free Trial
NASDAQ:PYPD

PolyPid Q4 2023 Earnings Report

PolyPid logo
$3.50 +0.02 (+0.57%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$3.46 -0.04 (-1.11%)
As of 08/22/2025 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PolyPid EPS Results

Actual EPS
-$3.97
Consensus EPS
-$2.17
Beat/Miss
Missed by -$1.80
One Year Ago EPS
N/A

PolyPid Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PolyPid Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

PolyPid Earnings Headlines

Roth Capital Issues Negative Forecast for PolyPid Earnings
Equities Analysts Issue Forecasts for PolyPid Q3 Earnings
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
PolyPid's (PYPD) "Buy" Rating Reaffirmed at HC Wainwright
PolyPid Releases Mid-2025 Financial Update
See More PolyPid Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PolyPid? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PolyPid and other key companies, straight to your email.

About PolyPid

PolyPid (NASDAQ:PYPD), a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

View PolyPid Profile

More Earnings Resources from MarketBeat